Stock Market Reviews

STOK (Stoke Therapeutics, Inc.) News

Get the latest news, insights, and market updates on STOK (Stoke Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Biotechs Are On A Big Run, And Two Stocks Have Buy Points
  Biotech stocks remain prevalent on the IBD 50 list of winning growth names. While many biotech names are extended, Stoke Therapeutics and Mirum Pharmaceuticals are both in or forming bases. Biotech stocks have made tremendous progress off April lows.
  Nov 28, 2025 - $STOK
• A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results
  Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, despite currently available therapies. See our latest analysis for Biogen. Biogen’s share price has gained real momentum in recent weeks, climbing 15.2% in the past month and 18.6% over the last 90 days, after a prolonged period of lackluster returns. Despite a recent flurry of product news and...
  Nov 18, 2025 - $STOK
• Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  BEDFORD, Mass., November 18, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on November 17, 2025, it granted stock options to purchase shares of common stock to Naomi Muse, the Company’s
  Nov 18, 2025 - $STOK
• Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
  – Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera
  Nov 17, 2025 - $STOK
• Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
  BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent
  Nov 17, 2025 - $STOK
• High Growth Tech Stocks In The US Market November 2025
  In the midst of a volatile U.S. market, where concerns about AI valuations have led to fluctuations in major indices like the Dow Jones and Nasdaq, investors are closely watching earnings reports and economic indicators amid a historic government shutdown. As tech stocks face renewed scrutiny, identifying high-growth opportunities requires careful consideration of companies' adaptability to current trends and their potential for innovation in an uncertain economic landscape.
  Nov 6, 2025 - $STOK
• Stoke Therapeutics Inc (STOK) Q3 2025 Earnings Call Highlights: Strong Financial Position and ...
  Stoke Therapeutics Inc (STOK) reports increased revenue and cash reserves, while advancing Zariva Nursen through Phase 3 trials.
  Nov 5, 2025 - $STOK
• All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy
  Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Nov 5, 2025 - $STOK
• Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
  BEDFORD, Mass., November 05, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesd
  Nov 5, 2025 - $STOK
• Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates
  Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -20.37% and +69.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $STOK